Amrize Ltd Reports Q3 2026 Financial Results
Amrize Ltd released its third-quarter 2026 financial results, reporting revenue of $3.77 billion and adjusted EPS of $1.05.
Stocks · News reference
Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Amrize Ltd Updates 2026 Revenue Guidance
Amrize Ltd has revised its full-year 2026 revenue outlook to a range of $12.2 billion to $12.4 billion.
Amrize Ltd Completes $1 Billion Share Repurchase Program
Amrize Ltd has successfully concluded its $1 billion share repurchase program, which was originally initiated on May 6, 2026.
Barclays Maintains Equal-Weight on Amrize, Lowers Price Target to $40
Barclays analyst Adam Seiden maintains Amrize (NYSE:AMRZ) with a Equal-Weight and lowers the price target from $55 to $40.
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 for XPHOZAH
Ardelyx announced results from a real-world analysis presented at the American Society of Nephrology (ASN) Kidney Week 2026, demonstrating serum phosphate reductions in dialysis patients treated with XPHOZAH.
Robbins LLP Urges ARDX Stockholders to Contact the Firm for Information About the Securities Class Action Against Ardelyx, Inc.
A securities class action has been filed against Ardelyx, Inc. (NASDAQ: ARDX) alleging the company misled investors about its commercial performance and growth prospects for its drug products IBSRELA and XPHOZAH. The lawsuit covers purchases between January 13, 2025 and August 6, 2026. On August 6, 2026, Ardelyx reduced its full-year 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance due to increased payer access barriers, causing the stock to drop 18% in one day from $4.87 to $4.00 per share.